Non-small cell lung cancer market seen reaching $36.9 billion by 2031

Allied Market Research says the global non-small cell lung cancer market is on track to more than double by 2031, driven by rising lung cancer prevalence and demand for immunotherapy, targeted therapy and chemotherapy. The report also flags high treatment costs and regulatory hurdles as restraints, while online pharmacy sales and Asia-Pacific growth emerge as key opportunities. Why it matters: - The non-small cell lung cancer market is projected to expand from $15.3 billion in 2021 to $36.9 billion by 2031. - That growth reflects rising demand for therapies used to treat one of the most common forms of lung cancer. - The forecast points to continued investment across treatment, distribution and drug development. What happened: - Allied Market Research published a report on the global non-small-cell lung cancer market on June 11, 2026. - The report projects a 9.3% CAGR from 2022 to 2031. - The market covers adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other NSCLC types. - The study also breaks the market down by chemotherapy, targeted therapy and immunotherapy, plus hospital pharmacy, drug store and retail pharmacy, and online pharmacy channels. - The report is available through a sample PDF report and a purchase inquiry page . The details: - NSCLC is caused by uncontrolled cell growth that forms a tumor. - Stage IV is the final stage, when tumors spread to other parts of the body. - NSCLC management can involve immunotherapy, targeted therapy and chemotherapy. - The report says it analyzes investment pockets, winning strategies, drivers, opportunities, market size, competitive landscape and market trends. - The report lists F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., AstraZeneca, Eli Lilly and Company, Merck & Co., Bristol-Myers Squibb Company, Celgene Corporation, Sanofi and Boehringer Ingelheim as top companies in the market. - Adenocarcinoma held nearly half the market in 2021 and is expected to keep the lead through 2031. - Large cell carcinoma is projected to post the fastest type growth, with an 11.3% CAGR from 2022 to 2031. - Targeted therapy held more than half the market in 2021 and is expected to remain the largest treatment segment. - Immunotherapy is projected to grow fastest among treatment types, at a 12.7% CAGR from 2022 to 2031. - Hospital pharmacies held more than two-thirds of the market in 2021 and are expected to stay the largest distribution channel. - Online pharmacy sales are projected to rise fastest, with a 15.1% CAGR from 2022 to 2031. - North America held about two-fifths of global revenue in 2021 and is expected to remain the largest regional market. - Asia-Pacific is projected to be the fastest-growing region, with a 10.5% CAGR from 2022 to 2031. - The report also identifies the U.S., Canada, Mexico, Germany, France, the UK, Italy, Spain, Japan, China, India, Brazil, Saudi Arabia and South Africa in its regional outlook. Between the lines: - Smoking and tobacco use are key drivers of market growth because they increase lung cancer prevalence. - High treatment costs and strict government approval rules are limiting market expansion. - The fastest growth in online pharmacy and immunotherapy suggests patients and providers are shifting toward more accessible channels and newer drug approaches. - The report’s cited opportunity in e-commerce channels may reflect broader healthcare buying behavior, but the release does not quantify that shift. What’s next: - The market forecast points to continued share gains for targeted therapy and immunotherapy through 2031. - Regional investment in Asia-Pacific is expected to support faster growth there than in other major markets. - Companies are likely to keep building out online pharmacy and digital sales channels as that segment grows. - For more information, Allied Market Research provides a sample PDF report and a purchase inquiry page .